Bevasiranib Acuity leading clinical compound.

About Acuity Pharmaceuticalsestablished in 2002 and is one Acuity Pharmaceuticals ophthalmic pharmaceutical company applying proprietary technologies for the treatment and prevention of eye diseases. Bevasiranib Acuity leading clinical compound, a small interfering RNA therapeutic targeting VEGF is in clinical trials for two of the leading causes of adult vision loss. Acuity recently completed a Phase II trial with bevasiranib in age-related macular degeneration and is currently conducting a Phase II trial for the treatment of diabetic macular edema. Acuity continues its drug development expertise to a growing pipeline of novel agents for ophthalmic conditions.

The Phase III clinical trial will further examine efficacy parameters, as well as dosing and dose scheduling regimens.. About BSCS:, in Colorado Springs, Colorado the Biological Sciences Curriculum Study , headquartered is a non-profit research and development organization, the efforts for all students of science and technology of science and technology by developing exemplary instructional materials that support its broad and effective use, the professional development and conducting research and evaluation studies. For more information, please visit.

Bevasiranib uses RNA interference to identify genes that promote the growth of blood vessels that lead to vision loss in wet AMD to bring silence.‘The Government’s recent proposals rapid access to quick access to quality healthcare and rid that the NHS the post-code lottery are welcome. However, we need to be anchored a close look at proposals for achieving these right in Act. We do not want lawyers ‘charter’, when a lot necessary money NHS drained away on complaints and arguments in.

Fully – registered optometrists and levy opticians who does not maintain their official proof Rebate with the Summer 2007 edition of the Bulletin of should be contacting to GOC registration team 020 7580 3898 .

waiting list huge tremendously, but the lack of capacity of the NHS being that hinders patients throughout the country of ever fast and equal access to treatment. The NHS has of growing and modernization, order at to react the changing needs in health care, and especially, to be quicker in patients and their families. Testing front Crab diagnosis or We are aware that the NHS Krebs care are last 10 years last 10 years, but the early diagnosis and treatment makes a significant difference to results. No patient should need to wait with pain for the treatment – and how long it wait for should not when live life however rotating to private sector, that treat for NHS patients do not offer a viable, future of.